Table 1.
Comparison of clinical characteristics of TB cases by three periods between the 2020 COVID-19 periods and 2017–2019 baseline.
| Variables | Period 1 | Period 2 | Period 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 2017–2019 | 2020 | P | 2017–2019 | 2020 | P | 2017–2019 | 2020 | P | |
| (N = 1368) | (N = 457) | (N = 1,497) | (N = 197) | (N = 1,532) | (N = 419) | ||||
| Treatment history | 0.352 | 0.427 | 0.870 | ||||||
| New cases | 1,305 (95.4) | 431 (94.3) | 1,399 (93.5) | 187 (94.9) | 1,441 (94.1) | 395 (94.3) | |||
| Retreated cases | 63 (4.6) | 26 (5.7) | 98 (6.5) | 10 (5.1) | 91 (5.9) | 24 (5.7) | |||
| Sputum smear results | <0.001 | <0.001 | <0.001 | ||||||
| Positive | 481 (35.2) | 204 (45.1) | 547 (36.5) | 107 (54.6) | 569 (37.3) | 199 (48.2) | |||
| Negative | 886 (64.8) | 248 (54.9) | 950 (63.5) | 89 (45.4) | 958 (62.8) | 214 (51.8) | |||
| X-ray inspection | 0.137 | 0.004 | 0.389 | ||||||
| With cavity | 176 (13.0) | 72 (15.8) | 230 (15.4) | 46 (23.5) | 212 (13.9) | 51 (12.2) | |||
| Without cavity | 1,176 (87.0) | 384 (84.2) | 1,262 (84.6) | 150 (76.5) | 1,318 (86.1) | 366 (87.8) | |||
| Sputum conversion of 2 months treatment | 0.593 | 0.230 | 0.198 | ||||||
| Yes | 400 (92.2) | 170 (93.4) | 456 (92.5) | 88 (88.9) | 470 (91.1) | 162 (94.2) | |||
| No | 34 (7.8) | 12 (6.6) | 37 (7.5) | 11 (11.1) | 46 (8.9) | 10 (5.8) | |||
| Treatment outcomesa | 0.078 | 0.560 | 0.058 | ||||||
| Favorable outcomes | 1,237 (90.4) | 400 (87.5) | 1,356 (90.6) | 166 (89.2) | 1,397 (91.2) | 305 (87.9) | |||
| Unfavorable outcomes | 131 (9.6) | 57 (12.5) | 141 (9.4) | 20 (10.8) | 135 (8.8) | 42 (12.1) | |||
a
Eleven and 72 TB cases diagnosed in period 2 and period 3 of 2020 were still on TB treatment, and these cases were excluded in the calculation and comparison of treatment outcomes in this study.